



GEDEON RICHTER

Inauguration of the new cGMP biopharmaceuticals facility in Bovenau, Germany

Budapest, 16 September 2024 - Gedeon Richter Plc. ("Richter") announces today, that its 100%-owned microbial biologics subsidiary, Richter BioLogics GmbH & Co KG, completed a major capacity expansion investment and officially opened its new cutting-edge biopharmaceutical cGMP (Current Good Manufacturing Practice) facility in Bovenau, Germany. The facility is equipped with the latest, state-of-the-art technology for clinical and large-scale commercial production and market supply of protein-based and plasmid DNA-based products. The new multi-purpose cGMP facility increases the total manufacturing area to approximately 10,000 square metres. The new 300L and 1500L production lines provide further flexibility to manufacture various products simultaneously, allowing up to 120 batches per year. The facility also includes large laboratories for analytical testing, warehousing and technical areas to optimize the flow of people and materials. By the end of 2024, the number of highly skilled local employees will have doubled to more than 400.

"This investment demonstrates Richter's strong commitment to the future of Richter BioLogics, to innovation and to GMP manufacturing of biopharmaceuticals. This new facility together with our existing facilities in Hungary provide for a fully integrated biologics R&D and manufacturing capability, allowing access to such medicines for patients worldwide" said Dr. Erik Bogsch, Head of the Biotechnology Business Unit of Gedeon Richter.

About Gedeon Richter Plc.

Gedeon Richter Plc. (www.gedeonrichter.com), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China, Latin America, and Australia. Having reached a market capitalization of EUR 4.3bn (USD 4.7bn) by the end of 2023, Richter's consolidated sales were approximately EUR 2.1bn (USD 2.3bn) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development, manufacture and commercialization.

For further information:

Investors: Róbert Réthy
Media: Zsuzsa Beke

+36 1 431 5680
+36 1 431 4888

Chemical Works of Gedeon Richter Plc.

Headquarters: H-1103 Budapest, Gyömrői út 19-21., Hungary • Postal address: H-1475 Budapest 10., Pf. 27., Hungary
Phone: +36 1 431 4000 • Fax: +36 1 260 6650, +36 1 260 4891 • Company Court of Budapest-Capital Tribunal Reg. No. Cg. 01-10-040944
EU Community VAT Identification No: HU 10484878 • Internet: www.gedeonrichter.com